# Drug-Drug Interaction Between R1_PBK_M2301 and R2_PBK_M2301 in Healthy Adults

> **NCT07017335** · PHASE1 · COMPLETED · sponsor: **Pharmbio Korea Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Drug-Drug Interaction Healthy Volunteers

## Interventions

- **DRUG:** R1_PBK_M2301(Levocloperastine 60mg)
- **DRUG:** R2_PBK_M2301 (Pelargonium sidoides extract)

## Key facts

- **NCT ID:** NCT07017335
- **Lead sponsor:** Pharmbio Korea Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07017335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07017335, "Drug-Drug Interaction Between R1_PBK_M2301 and R2_PBK_M2301 in Healthy Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07017335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*